US 11,834,681 B2
Cell culture medium for culturing organoid, culture method, and organoid
Toshiro Sato, Tokyo (JP); and Mami Matano, Tokyo (JP)
Assigned to KEIO UNIVERSITY, Tokyo (JP)
Filed by KEIO UNIVERSITY, Tokyo (JP)
Filed on Mar. 20, 2020, as Appl. No. 16/824,839.
Application 16/824,839 is a continuation of application No. 16/301,717, granted, now 11,407,980, previously published as PCT/JP2017/017681, filed on May 10, 2017.
Claims priority of application No. 2016-099995 (JP), filed on May 18, 2016.
Prior Publication US 2020/0231937 A1, Jul. 23, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/09 (2010.01)
CPC C12N 5/0693 (2013.01) [C12N 2500/02 (2013.01); C12N 2500/90 (2013.01); C12N 2501/105 (2013.01); C12N 2501/115 (2013.01); C12N 2501/415 (2013.01); C12N 2501/998 (2013.01)] 12 Claims
 
1. A method for producing an organoid comprising:
preparing an extracellular matrix,
adhering epithelial stem cells, epithelial cells, epithelial tumor cells, or tissue at least containing any one of these cells onto the extracellular matrix, and
forming the organoid by adding a cell culture medium for culturing the organoid and culturing the epithelial stem cells, the epithelial cells, the epithelial tumor cells, or tissue at least containing any one of these cells, after adhering,
wherein the cell culture medium for culturing the organoid comprises at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGF1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i) to iii):
i) Wnt agonist,
ii) bone morphogenetic protein (BMP) inhibitor, and
iii) transforming growth factor-β (TGF-β) inhibitor,
wherein the cell culture medium for culturing the organoid does not substantially contain EGF and p38 inhibitor.